SCLEROSTIN BINDING AGENT

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a he...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GRAHAM KEVIN, LATHAM JOHN, POPPLEWELL ANDY, SHEN WENYAN, ROBINSON MARTY KIM, HOFFMANN KELLY SUE, HENRY ALISTAIR JAMES, LU HSIENG SEN, PASZTY CHRISTOPHER, WINKLER DAVID, WINTERS AARON GEORGE, LAWSON ALASTAIR
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level.